Clinical Trials Logo

Filter by:
NCT ID: NCT05412836 Completed - Knee Osteoarthritis Clinical Trials

Intra-Articular Injection in Moderate Knee Osteoarthritis

Start date: March 22, 2022
Phase: N/A
Study type: Interventional

AqueousJoint is a new intra-articular (IA) injectable joint lubricant for patients suffering from knee Osteoarthritis developed by Liposphere LTD. AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation. The product goal is restoring cartilage its natural bio-lubrication properties. AqueousJoint is a surface lubricant that does not change the synovial fluid mechanical characterization but provides hydration protection from cartilage degradation and wear.

NCT ID: NCT05403320 Completed - Respiratory Failure Clinical Trials

Cuff Pressure Control and Evacuation of Subglottic Secretions To Prevent Pneumonia

Start date: June 6, 2022
Phase: N/A
Study type: Interventional

Multicenter, cluster randomized, controlled, open-label trial to assess if AnapnoGuard System can minimize tracheal microaspiration and the risk of ventilator-associated pneumonia when compared to standard treatment

NCT ID: NCT05384925 Completed - Diverticulitis Clinical Trials

Prior Abdominal Surgery: A Potential Risk Factor for Colonic Diverticulosis or Diverticulitis

Start date: April 12, 2020
Phase:
Study type: Observational

Background & Aims: Abnormal colonic pressure profiles have been associated with an increased risk of colonic diverticulosis. A surgical history is a known risk factor for abdominal adhesions, and these may lead to increased intraluminal colonic pressure. We assessed whether previous abdominal surgery is associated with colonic diverticulosis or diverticulitis. Methods: The investigators analyzed data from a prospective study of patients undergoing colonoscopy for different indications from 2020 through 2021. Patients completed a structured questionnaire concerning previous abdominal surgeries, dietary and lifestyle exposures including smoking and alcohol use, and co-morbidities.

NCT ID: NCT05383560 Completed - COVID-19 Clinical Trials

Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults

SH-MO-214
Start date: September 5, 2022
Phase: Phase 2
Study type: Interventional

Under protocol versions 1.01-1.06: The five recently emerged SARS-CoV2 variants that were designated as VOCs are the Alpha variant, Beta variant, Gamma variant, Delta variant and the Omicron variant. The current dominant Omicron variant was designated a VOC by WHO on Nov 26, 2021, and was found to comprise 85% of reported variants in late January 2022. Studies have shown that the prevalent Omicron mutations in the S1 subunit RBD region and NTD region could dramatically change the antigenic features of the viral spike, leading to significantly reduced neutralization Omicron harbors 30 signature mutations (>50% prevalence) of which 15 are in the S1 subunit RBD region and 8 are in the S1 subunit NTD region. Omicron is a highly contagious variant with threatening immune evasion capabilities even despite robust immune response. Initial modeling showed the Omicron variant being 2.8 times more infectious than the Delta variant. While current vaccines are losing protection against Omicron with respect to infection and mild disease, there is still considerable protection from hospitalisation and severe COVID-19, especially after a booster dose. The International Coalition of Medicines Regulatory Authorities (ICMRA) COVID-19 Omicron Variant Workshop encouraged the international scientific community and vaccine developers to look at alternative approaches to monovalent vaccines. In ICMRA's view, companies should also explore the feasibility of developing bivalent or multivalent variant vaccines to determine if they offer advantages to monovalent vaccines. As advised by ICMRA, the investigated vaccine, mRNA-1273.214 is a bivalent vaccine containing the ancestral SARS-CoV-2 and the Omicron variant spike sequences that will be evaluated as a heterologous boost. Under protocol version 1.07:The study will also investigate the safety, reactogenicity and immune response of the mRNA-1273.222 administered as a boost vaccine after primary series vaccination comprising 3 doses of an mRNA vaccine . This study hypothesizes that the peak level of antibodies against SARS CoV-2, will be at two weeks after the first study dose is administered, which is similar to other recent findings (Anderson et al., 2022).2.2.1. The bivalent mRNA-1273.222 vaccine contains mRNA encoding for the spike protein of BA.4/BA.5 as well as mRNA encoding for the original (ancestral Wuhan-Hu-1) strain of the SARS-CoV-2 virus.

NCT ID: NCT05365386 Completed - Actinic Keratoses Clinical Trials

Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.

Start date: May 17, 2022
Phase: N/A
Study type: Interventional

Evaluation of the Efficacy and Safety of a thermal fractional skin treatment system (Tixel) for the treatment of facial and/or scalp actinic keratoses

NCT ID: NCT05364931 Completed - Clinical trials for Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

PROXYMO-ADV
Start date: July 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.

NCT ID: NCT05361876 Completed - Health, Subjective Clinical Trials

Thermographic Analysis of Hemodynamics Changes Through & Following Wingate Test

Start date: March 1, 2021
Phase:
Study type: Observational

Remote sensing and measurements of hemodynamic changes in blood flow for Wingate Anaerobic test using a novel image processing algorithm. The algorithm calculates the heat distribution from the thermal images and assesses the changes in blood flow and temperatures in the torso and legs for each individual participant.

NCT ID: NCT05351463 Completed - Oral Surgery Clinical Trials

Papilla Suture Design Affects Papillary Postsurgical Dimensions

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The current prospective, randomized, controlled clinical trial aimed at comparing the impact of papillae suture technique on interdental papilla dimensions after periodontal surgery using a novel 3D intraoral scanning technique.

NCT ID: NCT05347680 Completed - Clinical trials for Difficult Intubation

A Comparison Between the Intubating Laryngeal Tube Suction and the Ambu AuraGain

Start date: September 19, 2019
Phase: N/A
Study type: Interventional

The intubating Laryngeal Tube Suction-Disposable is a new version of the Laryngeal Tube-Suction. It has a ventilator channel with a 13.5mm internal diameter, which enables the passage of an Endotracheal Tube with fiberoptic guidance. This study was designed to assess the Time fiberoptic endotracheal intubation using iLTS-D, in comparison with the and Ambu® AuraGain™ in adult patients.

NCT ID: NCT05344885 Completed - Parenting Clinical Trials

A Pilot Trial Examining Digital Parent Training Programs

Start date: April 28, 2022
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to preliminary examine the impact of a design mechanism aimed at increasing engagement in an unguided digital parent training program for child's behavior problems. Parents will be enrolled into one of two digital parent training intervention arms, dedifferentiated by their level of correspondence with the related deign mechanism.